Compare GSK Pharma with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA FRESENIUS KABI ONCO. GSK PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 32.4 22.1 146.3% View Chart
P/BV x 12.9 3.1 414.1% View Chart
Dividend Yield % 1.2 0.0 -  

Financials

 GSK PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
FRESENIUS KABI ONCO.
Mar-13
GSK PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs3,595176 2,042.6%   
Low Rs1,25379 1,596.2%   
Sales per share (Unadj.) Rs184.737.7 490.0%  
Earnings per share (Unadj.) Rs26.35.1 516.2%  
Cash flow per share (Unadj.) Rs29.26.7 433.8%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs126.342.5 296.9%  
Shares outstanding (eoy) m169.40158.23 107.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x13.13.4 388.8%   
Avg P/E ratio x92.225.0 369.0%  
P/CF ratio (eoy) x83.118.9 439.2%  
Price / Book Value ratio x19.23.0 641.6%  
Dividend payout %76.10-   
Avg Mkt Cap Rs m410,62620,135 2,039.4%   
No. of employees `0005.01.2 430.6%   
Total wages/salary Rs m5,372703 763.9%   
Avg. sales/employee Rs Th6,306.75,176.2 121.8%   
Avg. wages/employee Rs Th1,083.1610.4 177.4%   
Avg. net profit/employee Rs Th898.0699.6 128.4%   
INCOME DATA
Net Sales Rs m31,2815,963 524.6%  
Other income Rs m1,02318 5,684.3%   
Total revenues Rs m32,3045,981 540.1%   
Gross profit Rs m6,0091,430 420.2%  
Depreciation Rs m486258 188.4%   
Interest Rs m6-26 -23.1%   
Profit before tax Rs m6,5401,216 537.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m287-68 -421.4%   
Tax Rs m2,373342 693.5%   
Profit after tax Rs m4,454806 552.7%  
Gross profit margin %19.224.0 80.1%  
Effective tax rate %36.328.1 129.0%   
Net profit margin %14.213.5 105.4%  
BALANCE SHEET DATA
Current assets Rs m20,0615,102 393.2%   
Current liabilities Rs m14,5432,385 609.7%   
Net working cap to sales %17.645.6 38.7%  
Current ratio x1.42.1 64.5%  
Inventory Days Days57150 37.8%  
Debtors Days Days14113 12.4%  
Net fixed assets Rs m14,3435,148 278.6%   
Share capital Rs m1,694158 1,070.8%   
"Free" reserves Rs m19,7046,556 300.6%   
Net worth Rs m21,3986,732 317.9%   
Long term debt Rs m2952 0.2%   
Total assets Rs m39,11310,388 376.5%  
Interest coverage x1,091.0-45.8 -2,383.3%   
Debt to equity ratio x00.1 0.1%  
Sales to assets ratio x0.80.6 139.3%   
Return on assets %11.47.5 151.9%  
Return on equity %20.812.0 173.9%  
Return on capital %31.914.6 218.6%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m5345,298 10.1%   
Fx outflow Rs m7,0911,772 400.1%   
Net fx Rs m-6,5573,525 -186.0%   
CASH FLOW
From Operations Rs m3,9941,274 313.5%  
From Investments Rs m-1,433-1,204 119.0%  
From Financial Activity Rs m-3,584-196 1,827.4%  
Net Cashflow Rs m-1,023-126 810.1%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 81.0 62.6%  
Indian inst/Mut Fund % 10.2 0.3 3,400.0%  
FIIs % 23.8 9.6 247.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 9.1 169.2%  
Shareholders   102,036 42,599 239.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  ABBOTT INDIA  STRIDES PHARMA SCIENCE  

Compare GSK PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Nov 11, 2019 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS